Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 2c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11).

As of September 30, 2016, the Company had cash, cash equivalents, and short-term deposits of approximately $11.2 million.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• Lulu’s Fashion Lounge Holdings (LVLU) Misses Q2 EPS by 37c
• RenovoRx, Inc. (RNXT) Tops Q2 EPS by 2c